{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:53:01Z","timestamp":1757591581076},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1991,4]]},"abstract":"<jats:title>Abstract.<\/jats:title>\n<jats:p>Serum 5\u03b1-androstane-3\u03b1,17\u03b2-diolglucuronide (3\u03b1-AdiolG) levels were measured and the degree of hirsutism was scored in female outpatients complaining of excessive hair growth before and during treatment with cyproterone acetate. In a group of 16 patients with idiopathic hirsutism and in a group of 9 patients with either polycystic ovary syndrome and hirsutism or 21-hydroxylase deficiency and hirsutism, the serum 3\u03b1-AdiolG levels were significantly increased (p&lt;0.01) as compared with the serum 3\u03b1-AdiolG level in a control group of 13 apparently healthy women: 3\u03b1-AdiolG levels, median (range), being 5.3 (2.3-7.8) nmol\/l, 8.5 (4.1-10.4) nmol\/l, and 2.9 (1.5-5.2) nmol\/l, respectively. In contrast to a previous report, no correlation was found between the serum 3\u03b1-AdiolG levels and the Quetelet Index (N=18, R=0.42, p&gt;0.05), indicating an apparent ineffectiveness of the excessive androgen turnover in fat tissue. The use of the anti-androgen drug cyproterone acetate alone or in combination with ethinylestradiol in reverse sequential therapy did lower the 3\u03b1-AdiolG levels significantly (p&lt;0.01) together with a significant decrease (p&lt;0.01) in hirsutism score. From the results of this study we therefore conclude that 3\u03b1-AdiolG can be used as a parameter for peripheral androgen action before and during treatment with anti-androgens.<\/jats:p>","DOI":"10.1530\/acta.0.1240411","type":"journal-article","created":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T17:28:10Z","timestamp":1244741290000},"page":"411-416","update-policy":"http:\/\/dx.doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":4,"title":["Androstanediolglucuronide: A parameter for peripheral androgen activity before and during therapy with cyproterone acetate"],"prefix":"10.1093","volume":"124","author":[{"given":"Gabri\u00eblle A. E.","family":"Ponjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans A. M.","family":"de Rooy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huib L.","family":"Vader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["Acta Endocrinologica"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/124\/4\/acta_124_4_011.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/124\/4\/acta_124_4_011.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:12:50Z","timestamp":1676391170000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/124\/4\/411\/6769113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,4]]},"references-count":0,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/acta.0.1240411","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,4]]}}}